단장증후군(SBS) 시장 : 출시 약품 및 파이프라인 평가, 임상시험, 경쟁 구도
Short Bowel Syndrome (SBS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
상품코드
:
1284037
리서치사
:
GlobalData
발행일
:
2023년 05월
페이지 정보
:
영문 71 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
이 보고서는 세계의 단장증후군(SBS) 시장을 조사 분석하여 질병 현황, 출시 약품 및 파이프라인 의약품 평가, 현재와 미래의 경쟁 구도 등의 정보를 제공합니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질환 상황
제4장 출시 약품 평가
- 주요 출시 약품
- 개요 : 작용기전별
- 개요 : 투여 경로별
- 출시 약품 개요와 판매 예측
제5장 가격 결정과 상환 평가
제6장 파이프라인 의약품 평가
- 3상 파이프라인 의약품
- 개요 : 개발 단계별
- 개요 : 분자 유형별
- 개요 : 작용기전별
- 개요 : 투여 경로별
- 약품 고유 단계 전환 성공률(PTSR)과 승인 가능성(LoA)
- 치료 영역과 적응증 고유의 PTSR과 LoA
제7장 임상시험 평가
- 과거 개요
- 개요 : 단계별
- 개요 : 현황별
- 개요 : 진행중/계획중인 임상시험 단계별
- 가상 컴포넌트를 사용한 임상시험
- 지역적 개요
- 단일국/다국간 임상험 : 지역별
- 내역 : 상위 20개 스폰서와 단계별
- 내역 : 상위 20개 스폰서 현황별
- 개요 : 엔드포인트 현황별
- 개요 : 인종 및 민족별
- 등록 데이터
- 임성시험 시설 상위 20개국
- 세계의 주요 20개 시설
- 실현 가능성 분석 - 지역적 개요
- 실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
- 합병, 인수, 전략적 제휴 : 지역별
- 최근의 합병, 인수, 전략적 제휴
제9장 상업적 평가
제10장 향후의 시장 촉매
제11장 부록
LSH
영문 목차
Abstract
This reports provides a data-driven overview of the current and future competitive landscape in SBS therapeutics.
- There will be more than 94,000 diagnosed prevalent cases of SBS in 2023 in the 16 countries covered in GlobalData's epidemiology forecast.
- Glucagon-like peptide 2 receptor agonists play a key role in the current treatment paradigm for SBS.
- R&D activity in SBS is promising with three drugs in Phase III development.
- The clinical trials space in SBS includes both commercial and academic sponsors, with the US emerging as a key country for conducting Phase III trials.
- Four strategic alliances involving companies developing SBS assets were successfully completed during the past two years.
Scope
GlobalData's SBS: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the SBS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SBS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
- 1.1 Contents
- 1.2 Report Scope
- 1.3 List of Tables and Figures
- 1.4 Abbreviations
2 Key Findings
3 Disease Landscape
- 3.1 Disease Overview
- 3.2 Epidemiology Overview
- 3.3 Treatment Overview
4 Marketed Drugs Assessment
- 4.1 Leading Marketed Drugs
- 4.2 Overview by Mechanism of Action
- 4.3 Overview by Route of Administration
- 4.4 Marketed Drugs Profiles and Sales Forecasts
5 Pricing and Reimbursement Assessment
- 5.1 Annual Therapy Cost
- 5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
- 6.1 Phase III Pipeline Drugs
- 6.2 Overview by Development Stage
- 6.3 Overview by Molecule Type
- 6.4 Overview by Mechanism of Action
- 6.5 Overview by Route of Administration
- 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
- 6.7 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
- 7.1 Historical Overview
- 7.2 Overview by Phase
- 7.3 Overview by Status
- 7.4 Overview by Phase for Ongoing and Planned Trials
- 7.5 Trials with Virtual Components
- 7.6 Geographic Overview
- 7.7 Single-Country and Multinational Trials by Region
- 7.8 Top 20 Sponsors with Breakdown by Phase
- 7.9 Top 20 Sponsors with Breakdown by Status
- 7.10 Overview by Endpoint Status
- 7.11 Overview by Race and Ethnicity
- 7.12 Enrollment Data
- 7.13 Top 20 countries for Trial Sites
- 7.14 Top 20 Sites Globally
- 7.15 Feasibility Analysis - Geographic Overview
- 7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
- 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
- 8.2 Recent Mergers, Acquisitions, and Strategic Alliances
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
- 11.1 Methodology
- 11.2 Methodology - Sales Forecast
- 11.3 Methodology - Pricing and Reimbursement
- 11.4 Methodology - PTSR and LoA Analysis
- 11.5 About the Authors
- 11.6 Contact Us
- 11.7 Disclaimer
관련자료
